Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy
(SG) in combination with pembrolizumab given after surgery, is effective and safe compared to
the treatment of physician's choice (TPC) which includes either pembrolizumab ...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
Phase 1b Combo w/ Ribociclib and Alpelisib
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are
as follows:
Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals
Corporation).
Treatment Group 2: OP-1250 in combination wi...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and
safety of giredestrant plus everolimus compared with the physician's choice of endocrine
therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epid...
Age: 18 years - 66+
Gender: All
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with
Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Age: 18 - 90 years
Gender: Female
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
This is a phase 4, multi-center, open-label, prospective cohort study to evaluate the
clinical utility of Fluoroestradiol F18 (Cerianna) PET/CT to guide therapeutic management in
ER-positive, HER2-negative metastatic breast cancer patients with progressive disease o...
Age: 18 - 99 years
Gender: Female
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to
suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The
study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative ...
Age: 18 - 49 years
Gender: All
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in
participants with HER2-positive primary breast cancer who have received preoperative
chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a
findin...
Age: 18 years - 66+
Gender: All
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
thera...
Age: 50 - 70 years
Gender: All
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects
with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or
relapsed to standard of care (including pembrolizumab, if approved for that indicati...
Age: 18 years - 66+
Gender: All
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for
high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer
(DARE)
Age: Birth - 66+
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of
BT8009 given as a single agent and in combination with pembrolizumab in participants with
advanced solid tumors associated with Nectin-4 expression or in participants with a...
Age: 18 years - 66+
Gender: All
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
...
Age: 18 years - 66+
Gender: All
Increasing African Immigrant Women's Participation in Breast Cancer Screening
New York City (NYC) is home to a large and diverse immigrant population. Many of these groups
face significant barriers to preventive health care, including lack of insurance, poor health
care access and language difficulties. Most African immigrant women are likely...
Age: 18 - 74 years
Gender: All
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
This phase II trial studies how well FDG-PET/CT works in assessing the response of patients
with breast cancer that has spread to the bones or mostly to the bones (bone-dominant
metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in...
Age: 18 years - 66+
Gender: All
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer
who have no cancer remaining at surgery (either in the breast or underarm lymph node...
Age: 18 years - 66+
Gender: All
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses
of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Age: 18 years - 66+
Gender: All
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative breast
cancer that has spread to other places in the body. Using markers to prompt when scans sho...
Age: 18 years - 66+
Gender: All
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is
characterized by the lack of expression of estrogen receptor (ER), progesterone receptor
(PR), and HER-2 non-amplification. Women with TNBC tend to be younger, African American, and
...
Age: 18 years - 66+
Gender: Female